State of Tennessee Treasury Department Acquires New Stake in Genomic Health, Inc. (NASDAQ:GHDX)

State of Tennessee Treasury Department acquired a new stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 16,042 shares of the medical research company’s stock, valued at approximately $1,088,000.

A number of other hedge funds also recently bought and sold shares of the stock. Wakefield Asset Management LLLP increased its holdings in shares of Genomic Health by 2.1% in the 3rd quarter. Wakefield Asset Management LLLP now owns 7,280 shares of the medical research company’s stock worth $494,000 after purchasing an additional 150 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Genomic Health by 2.9% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,000 shares of the medical research company’s stock worth $394,000 after purchasing an additional 200 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Genomic Health by 12.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,301 shares of the medical research company’s stock worth $192,000 after purchasing an additional 372 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Genomic Health by 390.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 490 shares of the medical research company’s stock worth $33,000 after purchasing an additional 390 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Genomic Health by 29.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock worth $112,000 after purchasing an additional 441 shares in the last quarter. 93.87% of the stock is owned by institutional investors.

GHDX has been the subject of a number of research analyst reports. Piper Jaffray Companies lowered Genomic Health from an “overweight” rating to a “neutral” rating in a report on Monday, July 29th. JPMorgan Chase & Co. raised Genomic Health from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $60.00 to $72.00 in a report on Monday, July 29th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Zacks Investment Research raised Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a report on Wednesday, July 31st. Finally, ValuEngine downgraded Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, September 10th. Ten investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $69.86.

Shares of GHDX stock traded down $0.44 on Wednesday, reaching $63.44. The stock had a trading volume of 12,537,000 shares, compared to its average volume of 1,049,573. The stock has a market cap of $2.38 billion, a P/E ratio of 60.42 and a beta of 0.90. Genomic Health, Inc. has a 1 year low of $50.77 and a 1 year high of $90.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.96 and a current ratio of 5.96. The company has a 50 day simple moving average of $68.03 and a 200 day simple moving average of $64.47.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Monday, November 11th. The medical research company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.11. Genomic Health had a return on equity of 19.62% and a net margin of 12.81%. On average, equities research analysts anticipate that Genomic Health, Inc. will post 1.58 earnings per share for the current fiscal year.

In related news, insider Laura Leber sold 13,183 shares of Genomic Health stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $70.94, for a total transaction of $935,202.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Steven Shak sold 25,000 shares of Genomic Health stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $71.47, for a total value of $1,786,750.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 118,175 shares of company stock worth $8,381,145. Company insiders own 31.30% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: Do back-end load funds outperform no-load funds?

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.